Skip to main content
. 2017 Sep 18;8(5-6):314–324. doi: 10.1007/s12672-017-0307-4

Table 2.

Clinicopathological features of thyroid cancer, mRNA expression for GHRH and GHRHR, and immunohistochemical staining for GHRHR

Clinicopathological features mRNA expression GHRH mRNA expression GHRHR Protein expression GHRHR
Not detectable Positive Not detectable Positive Negative Positive
Number of cases (n) 18 14 17 14 10 31
Age at diagnosis (n (%))
 ≤ 45 14 (46.7) 7 (23.3) 11 (37.9) 10 (34.5) 7 (17.5) 18 (45.0)
 > 45 3 (10.0) 6 (20.0) 4 (13.8) 4 (13.8) 3 (7.5) 12 (30.0)
Gender (n (%))
 Female 12 (40.0) 12 (40.0) 13 (44.8) 11 (37.9) 8 (20.0) 26 (65.0)
 Male 5 (16.7) 1 (3.3) 2 (6.9) 3 (10.4) 2 (5.0) 4 (10.0)
Tumor size (n (%))
 ≤ 2 cm 7 (24.1) 6 (20.7) 6 (21.4) 7 (25.0) 1 (2.5) 14 (35.9)
 > 2 cm 8 (27.6) 8 (27.6) 10 (35.7) 5 (17.9) 9 (23.1) 15 (38.5)
Number of tumors (n (%))
 Single 6 (24.0) 7 (28.0) 5 (20.0) 8 (32.0) 3 (8.1) 19 (51.4)
 Multiple 6 (24.0) 6 (24.0) 9 (36.0) 3 (12.0) 5 (13.5) 10 (27.0)
Vascular invasion (n (%))
 Absent 2 (9.1) 8 (36.4) 8 (30.8) 6 (23.1) 3 (8.6) 13 (37.1)
 Present 9 (40.9) 3 (13.6) 7 (26.9) 5 (19.2) 5 (14.3) 14 (40.0)
Lymph node metastasis (n (%))
 Absent 2 (12.5) 5 (31.3) 3 (20.0) 4 (26.7) 0 (0.0) 12 (48.0)
 Present 8 (50.0) 1 (6.2) 6 (40.0) 2 (13.3) 5 (20.0) 8 (32.0)
Extrathyroidal invasion (n (%))
 Absent 8 (26.7) 9 (30.0) 9 (32.1) 8 (28.6) 7 (21.2) 16 (48.5)
 Present 9 (30.0) 4 (13.3) 7 (25.0) 4 (14.3) 3 (9.1) 7 (21.2)
Lymphocytic infiltrate (n (%))
 Absent 9 (30.1) 7 (23.3) 9 (30.1) 7 (23.3) 7 (17.5) 12 (30.0)
 Present 7 (23.3) 7 (23.3) 7 (23.3) 7 (23.3) 2 (5.0) 19 (47.5)
MAPK alterations (n (%))
 Absent 6 (18.7) 8 (25.0) 6 (19.4) 8 (25.8) 4 (10.0) 9 (22.5)
 Present 12 (37.6) 6 (18.7) 11 (35.4) 6 (19.4) 5 (12.5) 22 (55.0)

Legend: The number of cases varies along features, according to the number of patients with the clinical information available